Next-Generation Cell Isolation for Gene and Cell Therapies
Proteios is developing a novel device that reversibly captures target cells with unprecedented efficiency and ease of use. No antibodies, beads or tags remain after isolation.
The Problem
Existing methods for immune cell isolation are incapable of isolating cells using multiple markers.
Our Solution
Our device (currently in version 3) enables highly efficiency, high yield, automated cell Isolation, Activation, Transduction, and Expansion, empowering researchers and clinicians with better data and faster insights. Cells with multiple targets can be isolated in a closed system.
News
March 12, 2025 - Proteios is awarded the UW Environmental Health & Safety Lab Safety Award
For their commitment to Laboratory Safety and Promoting a Culture of Safety.
June 18, 2023- Proteios is excited to receive a $1.7M grant from the Andy Hill CARE Fund
Proteios receives a $1.7M grant from the Andy Hill CARE Fund to commercialize our next-generation cell isolation and cell therapy manufacturing platform. When commercialized, Proteios will support the isolation of over 20 cell subtypes.
Our Leadership Team
Bob Snyder, Ph.D./MBA
Bob is Cofounder and CEO at Proteios and has over 30 years’ experience in life science research and commercialization. He has a Ph.D. in Biochemistry from the University of California, Santa Barbara and an MBA from the University of Chicago Graduate School of Business. Bob previously held executive positions with Abbott Laboratories, Merck & Co., FEI Company, and Elsevier Science.
François Baneyx, Ph.D.
François is Cofounder and Scientific Advisor at Proteios and is currently Charles W.H. Matthaei Professor of Chemical Engineering, Director of CoMotion, and Vice Provost for Innovation at the University of Washington. He has a Ph.D. in Chemical Engineering from the University of Texas and is inventor of Proteios’ protein purification technology.
